Sugi Predict

Sugi Predict / Compounds / SCHEMBL5694185

SCHEMBL5694185

SCHEMBL5694185

Nc1nc2[nH]cnc2c(=O)n1C(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ CYP1A2 P05177 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.41
▸ POLB P06746 3/20 0.41
▸ PKM P14618 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ PDPK1 O15530 1/20 0.38
▸ P2RX4 Q99571 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.35
▸ TYMP P19971 1/20 0.35
▸ F2 P00734 2/20 0.34
▸ PNP P00491 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740456 0.81 ALDH1A1 (0.36) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6821768 0.80 GDA (0.39) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL5694071 0.79 KMT2A (0.41) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL218666 0.79 GDA (0.34) CYP1A2LMNAPNPMAPT
SCHEMBL5694191 0.79 NPC1 (0.51) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6267419 0.79 PNP (0.40) NPC1RAB9AKMT2ASMN1; SMN2CYP1A2
SCHEMBL8583444 0.78 KMT2A (0.42) KMT2AMEN1KDM4ETDP1PNP
Bromide SCHEMBL8165610 0.78 GDA (0.33) CYP1A2LMNAPNPMAPT
SCHEMBL2940012 0.76 KDM4E (0.46) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL453202 0.76 GDA (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924393-A Monomer of 3' -mercapto nucleoside analogue and its synthesis process 天津兴博润生物制药有限公司 2024-04-26 — — CN claimed
WO-1992011276-A1 NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-07-09 — — WO claimed
US-20240150391-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORP (US) 2024-05-09 — — US disclosed
CN-117924393-A Monomer of 3' -mercapto nucleoside analogue and its synthesis process 天津兴博润生物制药有限公司 2024-04-26 — — CN disclosed
EP-4286519-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORPORATION (US) 2023-12-06 — — EP disclosed
EP-3137479-B1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORP (US) 2023-08-30 — — EP disclosed
US-11739114-B2 Oligonucleotide compositions and methods of making the same GERON CORPORATION (US) 2023-08-29 — — US disclosed
CN-111228288-A Oligonucleotide composition and method for preparing same 美国杰龙生物医药公司 2020-06-05 — — CN disclosed
CN-106459134-B Oligonucleotide composition and method for preparing same 美国杰龙生物医药公司 2020-02-18 — — CN disclosed
US-10392418-B2 Oligonucleotide compositions and methods of making the same GERON CORPORATION (US) 2019-08-27 — — US disclosed
US-20180016293-A1 Oligonucleotide Compositions and Methods of Making the Same BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2018-01-18 — — US disclosed
EP-3137479-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME Geron Corporation (US) 2017-03-08 — — EP disclosed
WO-2015168310-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORPORATION (US) 2015-11-05 — — WO disclosed
EP-1694842-A1 RNA AMIDATES AND THIOAMIDATES FOR RNAI Geron Corporation (US) 2006-08-30 — — EP disclosed
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 — — US disclosed
EP-1645561-A1 METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2006-04-12 — — EP disclosed
WO-2005047506-A1 RNA AMIDATES AND THIOAMIDATES FOR RNAI GERON CORPORATION (US) 2005-05-26 — — WO disclosed
EP-0882059-B1 SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES LYNX THERAPEUTICS INC (US) 2002-02-06 — — EP disclosed
WO-1992011276-A1 NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-07-09 — — WO disclosed
EP-0105486-A2 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents SYNTEX (U.S.A.) INC. (US) 1984-04-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739114-B2 Oligonucleotide compositions and methods of making the same RNGTT, NSUN2, POLN NPC1 4312/4885RAB9A 4870/4885KMT2A 4055/4885
US-10392418-B2 Oligonucleotide compositions and methods of making the same RNGTT, NSUN2, POLN NPC1 4312/4885RAB9A 4870/4885KMT2A 4055/4885
US-20180016293-A1 Oligonucleotide Compositions and Methods of Making the Same RNGTT, NSUN2, POLN NPC1 4312/4885RAB9A 4870/4885KMT2A 4055/4885
US-20240150391-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME RNGTT, NSUN2, POLN NPC1 4296/4885RAB9A 4873/4885KMT2A 4167/4885
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB NPC1 2171/4885RAB9A 3223/4885KMT2A 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.